nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical Universitynefr-232Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESЭНДОТОКСИН И ХРОНИЧЕСКОЕ ВОСПАЛЕНИЕ ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕКENDOTOXIN AND CHRONIC INFLAMMATION IN PATIENTS WITH CHRONIC KIDNEY DISEASEВатазинА. В.VatazinA. V.

Ватазин Андрей Владимирович, доктор медицинских наук, профессор. 

Руководитель отдела трансплантологии, нефрологии и хирургической гемокоррекции. 

129110, Москва, ул. Щепкина, д. 61/2, корп. 6.

Andrey V. Vatazin, MD, PhD, Professor of medicine, DMedSci. 

Head of the Department of Transplantation, Nephrology and Surgical hemocorrection. 

129110, Moscow, Shchepkin Str., 61/2, building 6. 

vatazin@yandex.ruЗулькарнаевА. Б.ZulkarnaevA. B.

Зулькарнаев Алексей Батыргараевич, доктор медицинских наук.

Старший научный сотрудник хирургического отделения трансплантологии и диализа.

129110, Москва, ул. Щепкина, д. 61/2, корп. 6. 

Alexey B. Zulkarnaev, MD, PhD, DMedSci. 

Senior Researcher of transplantation and dialysis surgical department. 

129110, Moscow, Shchepkin Str., 61/2, building 6. 

7059899@gmail.comМосковский областной научно-исследовательский клинический институт им. М.Ф. ВладимирскогоРоссияMoscow regional research and clinical institute named after M.F. VladimirskyRussian Federation2016030320172062632Copyright © Ватазин А.В., Зулькарнаев А.Б., 20172017Ватазин А.В., Зулькарнаев А.Б.Vatazin A.V., Zulkarnaev A.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/232

Эндотоксин – облигатный компонент клеточной стенки грамотрицательных бактерий – один из основных этиологических факторов хронического воспаления у больных хронической болезнью почек. Тяжесть эндотоксинемии возрастает по мере прогрессирования почечной недостаточности. Основными источниками эндотоксина являются микробиом толстой кишки, а также биопленки, формируемые бактериями, в системе водоподготовки, венозных катетеров и т.д. Эндотоксин вызывает различные стойкие нарушения гомеостаза: клеточного и гуморального иммунитета, метаболические расстройства и др. Коррекция указанных нарушений представляет собой сложную задачу. Эндотоксинемия у больных хронической болезнью почек значительно ухудшает результаты лечения и рост летальности.

Endotoxin – obligatory component of gram-negative bacteria cell wall – one of the main etiological factors of chronic inflammation in patients with chronic kidney disease. Endotoxinemia severity increases with the progression of renal failure. The main sources of endotoxin are colon microbiome, as well as the biofilm formed by bacteria in the water treatment system, venous catheters, etc. Endotoxin causes persistent violations of homeostasis: cellular and humoral immunity, metabolic disorders, etc. The correction of these disorders is a complex problem. Endotoxinemia in patients with chronic kidney disease significantly affects the results of treatment and increases mortality.

эндотоксинвоспалениехроническая болезнь почекгемодиализendotoxininflammationchronic kidney diseasehemodialysisReferencesБикбов БТ, Томилина НА. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации в 1998-2013 гг. Отчет по данным российского регистра заместительной почечной терапии. Часть первая. Нефрология и диализ 2015; 17(3, приложение): 5-111 [Bikbov BT, Tomilina NA. Zamestitel’naja terapija terminal’noj hronicheskoj pochechnoj nedostatochnosti v rossijskoj federacii v 1998-2013 gg. Otchet po dannym rossijskogo registra zamestitel’noj pochechnoj terapii. Chast’ pervaja. Nefrologija i dializ 2015; 17(3, prilozhenie): 5-111]Бикбов БТ, Томилина НА. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации в 1998-2013 гг. Отчет по данным российского регистра заместительной почечной терапии. Часть первая. Нефрология и диализ 2015; 17(3, приложение): 5-111 [Bikbov BT, Tomilina NA. Zamestitel’naja terapija terminal’noj hronicheskoj pochechnoj nedostatochnosti v rossijskoj federacii v 1998-2013 gg. Otchet po dannym rossijskogo registra zamestitel’noj pochechnoj terapii. Chast’ pervaja. Nefrologija i dializ 2015; 17(3, prilozhenie): 5-111]Terawaki H, Yokoyama, Yamada Y et al. Low-grade endotoxemia contributes to chronic inflammation in hemodialysis patients: examination with a novel lipopolysaccharide detection method. Ther Apher Dial 2010; 14(5):477-482. doi: 10.1111/j.17449987.2010.00815.xTerawaki H, Yokoyama, Yamada Y et al. Low-grade endotoxemia contributes to chronic inflammation in hemodialysis patients: examination with a novel lipopolysaccharide detection method. Ther Apher Dial 2010; 14(5):477-482. doi: 10.1111/j.17449987.2010.00815.xMcIntyre CW, Harrison LE, Eldehni MT et al. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6(1):133-141. doi: 10.2215/CJN.04610510McIntyre CW, Harrison LE, Eldehni MT et al. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6(1):133-141. doi: 10.2215/CJN.04610510Cardoso PG, Macedo GC, Azevedo V et al. Brucella spp noncanonical LPS: structure, biosynthesis, and interaction with host immune system. Microb Cell Fact 2006; 5:13Cardoso PG, Macedo GC, Azevedo V et al. Brucella spp noncanonical LPS: structure, biosynthesis, and interaction with host immune system. Microb Cell Fact 2006; 5:13Villar J, Maca-Meyer N, Perez-Mendez L et al. Bench-tobedside review: understanding genetic predisposition to sepsis. Crit Care 2004; 8(3): 180-189Villar J, Maca-Meyer N, Perez-Mendez L et al. Bench-tobedside review: understanding genetic predisposition to sepsis. Crit Care 2004; 8(3): 180-189Gyorfy Z, Duda E, Vizler C. Interactions between LPS moieties and macrophage pattern recognition receptors. Vet Immunol Immunopathol 2013; 152(1-2):28-36. doi: 10.1016/j.vetimm.2012.09.020Gyorfy Z, Duda E, Vizler C. Interactions between LPS moieties and macrophage pattern recognition receptors. Vet Immunol Immunopathol 2013; 152(1-2):28-36. doi: 10.1016/j.vetimm.2012.09.020Аниховская ИА, Опарина ОН, Яковлева ММ, Яковлев МЮ. Кишечный эндотоксин как универсальный фактор адаптации и патогенеза общего адаптационного синдрома. Физиология человека 2006; 32(2): 87-91Аниховская ИА, Опарина ОН, Яковлева ММ, Яковлев МЮ. Кишечный эндотоксин как универсальный фактор адаптации и патогенеза общего адаптационного синдрома. Физиология человека 2006; 32(2): 87-91Ward PA. Role of C5 activation products in sepsis. ScientificWorldJournal 2010; 10:2395-2402. doi: 10.1100/tsw.2010.216Ward PA. Role of C5 activation products in sepsis. ScientificWorldJournal 2010; 10:2395-2402. doi: 10.1100/tsw.2010.216Kozarcanin H, Lood C, Munthe-Fog L et al. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation. J Thromb Haemost 2016; 14(3):531-545. doi: 10.1111/jth.13208Kozarcanin H, Lood C, Munthe-Fog L et al. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation. J Thromb Haemost 2016; 14(3):531-545. doi: 10.1111/jth.13208Esmon CT, Xu J, Lupu F. Innate immunity and coagulation. J Thromb Haemost 2011; 9 Suppl 1:182-188. doi: 10.1111/j.15387836.2011.04323.xEsmon CT, Xu J, Lupu F. Innate immunity and coagulation. J Thromb Haemost 2011; 9 Suppl 1:182-188. doi: 10.1111/j.15387836.2011.04323.xLassenius MI, Pietilainen KH, Kaartinen K et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 2011; 34(8):1809-1815. doi: 10.2337/dc10-2197Lassenius MI, Pietilainen KH, Kaartinen K et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 2011; 34(8):1809-1815. doi: 10.2337/dc10-2197Boutagy NE, McMillan RP, Frisard MI et al. Metabolic endotoxemia with obesity: Is it real and is it relevant? Biochimie 2016; 124:11-20. doi: 10.1016/j.biochi.2015.06.020Boutagy NE, McMillan RP, Frisard MI et al. Metabolic endotoxemia with obesity: Is it real and is it relevant? Biochimie 2016; 124:11-20. doi: 10.1016/j.biochi.2015.06.020Белоглазов ВА, Климчук АВ, Гордиенко АИ и др. Динамика показателей гуморального антиэндотоксинового иммунитета и уровень С-реактивного белка у больных хронической болезнью почек, находящихся на программном гемодиализе, при четырехлетнем наблюдении. Нефрология и диализ 2013; 15(2): 140-143 [Beloglazov VA, Klimchuk AV, Gordienko AI i dr. Dinamika pokazatelej gumoral'nogo antijendotoksinovogo immuniteta i uroven' S-reaktivnogo belka u bol'nyh hronicheskoj bolezn'ju pochek, nahodjashhihsja na programmnom gemodialize, pri chetyrehletnem nabljudenii. Nefrologija i dializ 2013; 15(2): 140-143]Белоглазов ВА, Климчук АВ, Гордиенко АИ и др. Динамика показателей гуморального антиэндотоксинового иммунитета и уровень С-реактивного белка у больных хронической болезнью почек, находящихся на программном гемодиализе, при четырехлетнем наблюдении. Нефрология и диализ 2013; 15(2): 140-143 [Beloglazov VA, Klimchuk AV, Gordienko AI i dr. Dinamika pokazatelej gumoral'nogo antijendotoksinovogo immuniteta i uroven' S-reaktivnogo belka u bol'nyh hronicheskoj bolezn'ju pochek, nahodjashhihsja na programmnom gemodialize, pri chetyrehletnem nabljudenii. Nefrologija i dializ 2013; 15(2): 140-143]Feroze U, Kalantar-Zadeh K, Sterling KA et al. Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. J Ren Nutr 2012; 22(3):317-326. doi: 10.1053/j.jrn.2011.05.004Feroze U, Kalantar-Zadeh K, Sterling KA et al. Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. J Ren Nutr 2012; 22(3):317-326. doi: 10.1053/j.jrn.2011.05.004Lau WL, Kalantar-Zadeh K, Vaziri ND. The Gut as a Source of Inflammation in Chronic Kidney Disease. Nephron 2015; 130(2):92-98. doi: 10.1159/000381990Lau WL, Kalantar-Zadeh K, Vaziri ND. The Gut as a Source of Inflammation in Chronic Kidney Disease. Nephron 2015; 130(2):92-98. doi: 10.1159/000381990Sabatino A, Regolisti G, Brusasco I et al. Alterations of intestinal barrier and microbiota in chronic kidney disease. Nephrol Dial Transplant 2015; 30(6):924-933. doi: 10.1093/ndt/gfu287Sabatino A, Regolisti G, Brusasco I et al. Alterations of intestinal barrier and microbiota in chronic kidney disease. Nephrol Dial Transplant 2015; 30(6):924-933. doi: 10.1093/ndt/gfu287Shi K, Wang F, Jiang H et al. Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. Dig Dis Sci 2014; 59(9):2109-2117. doi: 10.1007/s10620-014-3202-7Shi K, Wang F, Jiang H et al. Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. Dig Dis Sci 2014; 59(9):2109-2117. doi: 10.1007/s10620-014-3202-7Hazzah WA, Hashish MH, El-Koraie AF et al. Circulating bacterial DNA fragments in chronic hemodialysis patients. Saudi J Kidney Dis Transpl 2015; 26(6):1300-1304. doi: 10.4103/13192442.168689Hazzah WA, Hashish MH, El-Koraie AF et al. Circulating bacterial DNA fragments in chronic hemodialysis patients. Saudi J Kidney Dis Transpl 2015; 26(6):1300-1304. doi: 10.4103/13192442.168689Marinho AC, Polay AR, Gomes BP. Accuracy of Turbidimetric Limulus Amebocyte Lysate Assay for the Recovery of Endotoxin Interacted with Commonly Used Antimicrobial Agents of Endodontic Therapy. J Endod 2015; 41(10):1653-1659. doi: 10.1016/j.joen.2015.05.020Marinho AC, Polay AR, Gomes BP. Accuracy of Turbidimetric Limulus Amebocyte Lysate Assay for the Recovery of Endotoxin Interacted with Commonly Used Antimicrobial Agents of Endodontic Therapy. J Endod 2015; 41(10):1653-1659. doi: 10.1016/j.joen.2015.05.020Wong J, Vilar E, Farrington K. Endotoxemia in end-stage kidney disease. Semin Dial; 28(1):59-67. doi: 10.1111/sdi.12280Wong J, Vilar E, Farrington K. Endotoxemia in end-stage kidney disease. Semin Dial; 28(1):59-67. doi: 10.1111/sdi.12280Shimizu T, Obata T, Sonoda H et al. Diagnostic potential of endotoxin scattering photometry for sepsis and septic shock. Shock 2013; 40(6):504-511. doi: 10.1097/SHK.0000000000000056Shimizu T, Obata T, Sonoda H et al. Diagnostic potential of endotoxin scattering photometry for sepsis and septic shock. Shock 2013; 40(6):504-511. doi: 10.1097/SHK.0000000000000056Ding JL, Ho B. Endotoxin detection-from limulus amebocyte lysate to recombinant factor C. Subcell Biochem 2010; 53:187-208. doi: 10.1007/978-90-481-9078-2_9Ding JL, Ho B. Endotoxin detection-from limulus amebocyte lysate to recombinant factor C. Subcell Biochem 2010; 53:187-208. doi: 10.1007/978-90-481-9078-2_9Yaguchi A, Yuzawa J, Klein DJ et al. Combining intermediate levels of the Endotoxin Activity Assay (EAA) with other biomarkers in the assessment of patients with sepsis: results of an observational study. Crit Care 2012; 16(3):R88. doi: 10.1186/cc11350Yaguchi A, Yuzawa J, Klein DJ et al. Combining intermediate levels of the Endotoxin Activity Assay (EAA) with other biomarkers in the assessment of patients with sepsis: results of an observational study. Crit Care 2012; 16(3):R88. doi: 10.1186/cc11350Poesen R, Ramezani A, Claes K et al. Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular Disease, and Progression of Kidney Disease among Patients with CKD. Clin J Am Soc Nephrol 2015; 10(9):1525-1533. doi: 10.2215/CJN.03100315.Poesen R, Ramezani A, Claes K et al. Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular Disease, and Progression of Kidney Disease among Patients with CKD. Clin J Am Soc Nephrol 2015; 10(9):1525-1533. doi: 10.2215/CJN.03100315.Raj DS, Shah VO, Rambod M et al. Association of soluble endotoxin receptor CD14 and mortality among patients undergoing hemodialysis. Am J Kidney Dis 2009; 54(6):1062-1071. doi: 10.1053/j.ajkd.2009.06.028Raj DS, Shah VO, Rambod M et al. Association of soluble endotoxin receptor CD14 and mortality among patients undergoing hemodialysis. Am J Kidney Dis 2009; 54(6):1062-1071. doi: 10.1053/j.ajkd.2009.06.028Cobo G, Qureshi AR, Lindholm B, Stenvinkel P. C-reactive Protein: Repeated Measurements will Improve Dialysis Patient Care. Semin Dial 2016; 29(1):7-14. doi: 10.1111/sdi.12440Cobo G, Qureshi AR, Lindholm B, Stenvinkel P. C-reactive Protein: Repeated Measurements will Improve Dialysis Patient Care. Semin Dial 2016; 29(1):7-14. doi: 10.1111/sdi.12440Cross AS. Development of an anti-endotoxin vaccine for sepsis. Subcell Biochem 2010; 53: 285-302Cross AS. Development of an anti-endotoxin vaccine for sepsis. Subcell Biochem 2010; 53: 285-302Muller-Loennies S, Brade L, Brade H. Neutralizing and cross-reactive antibodies against enterobacterial lipopolysaccharide. Int J Med Microbiol 2007; 297(5): 321-340Muller-Loennies S, Brade L, Brade H. Neutralizing and cross-reactive antibodies against enterobacterial lipopolysaccharide. Int J Med Microbiol 2007; 297(5): 321-340Santos MF, New RR, Andrade GR et al. Lipopolysaccharide as an antigen target for the formulation of a universal vaccine against Escherichia coli O111 strains. Clin Vaccine Immunol 2010; 17(11): 1772-1780Santos MF, New RR, Andrade GR et al. Lipopolysaccharide as an antigen target for the formulation of a universal vaccine against Escherichia coli O111 strains. Clin Vaccine Immunol 2010; 17(11): 1772-1780Harkin DW, Arnold R, Hoper M. Anti-endotoxin hyperimmune globulin attenuates portal cytokinaemia, phagocytic cell priming, and acute lung injury after lower limb ischaemiareperfusion injury. Eur J Vasc Endovasc Surg 2007; 33(3): 330-339Harkin DW, Arnold R, Hoper M. Anti-endotoxin hyperimmune globulin attenuates portal cytokinaemia, phagocytic cell priming, and acute lung injury after lower limb ischaemiareperfusion injury. Eur J Vasc Endovasc Surg 2007; 33(3): 330-339Pini A, Falciani C, Mantengoli E et al. A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo. FASEB J 2010; 24(4): 1015-1022Pini A, Falciani C, Mantengoli E et al. A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo. FASEB J 2010; 24(4): 1015-1022Li J, Shang G, You M et al. Endotoxin removing method based on lipopolysaccharide binding protein and polyhydroxyalkanoate binding protein PhaP. Biomacromolecules 2011; 12(3): 602-608Li J, Shang G, You M et al. Endotoxin removing method based on lipopolysaccharide binding protein and polyhydroxyalkanoate binding protein PhaP. Biomacromolecules 2011; 12(3): 602-608Liu D, Lu F, Qin G et al. C1 inhibitor-mediated protection from sepsis. J Immunol 2007; 179(6): 3966-3972Liu D, Lu F, Qin G et al. C1 inhibitor-mediated protection from sepsis. J Immunol 2007; 179(6): 3966-3972Kaconis Y, Kowalski I, Howe J et al. Biophysical mechanisms of endotoxin neutralization by cationic amphiphilic peptides. Biophys J 2011; 100(11): 2652-6261Kaconis Y, Kowalski I, Howe J et al. Biophysical mechanisms of endotoxin neutralization by cationic amphiphilic peptides. Biophys J 2011; 100(11): 2652-6261Peri F, Piazza M. Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists. Biotechnol Adv 2012; 30(1): 251-260Peri F, Piazza M. Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists. Biotechnol Adv 2012; 30(1): 251-260Fujita T. Molecular mechanism of endotoxin tolerance. Hepatology 2009; 50(4): 1322Fujita T. Molecular mechanism of endotoxin tolerance. Hepatology 2009; 50(4): 1322Brandenburg K, Heinbockel L, Correa W et al. Peptides with dual mode of action: Killing bacteria and preventing endotoxininduced sepsis. Biochim Biophys Acta 2016; 1858(5):971-979. doi: 10.1016/j.bbamem.2016.01.011Brandenburg K, Heinbockel L, Correa W et al. Peptides with dual mode of action: Killing bacteria and preventing endotoxininduced sepsis. Biochim Biophys Acta 2016; 1858(5):971-979. doi: 10.1016/j.bbamem.2016.01.011Sun Y, Shang D. Inhibitory Effects of Antimicrobial Peptides on Lipopolysaccharide-Induced Inflammation. Mediators Inflamm 2015; 2015:167572. doi: 10.1155/2015/167572Sun Y, Shang D. Inhibitory Effects of Antimicrobial Peptides on Lipopolysaccharide-Induced Inflammation. Mediators Inflamm 2015; 2015:167572. doi: 10.1155/2015/167572Moraes C, Fouque D, Amaral AC et al. Trimethylamine N-Oxide From Gut Microbiota in Chronic Kidney Disease Patients: Focus on Diet. J Ren Nutr 2015; 25(6):459-465. doi: 10.1053/j.jrn.2015.06.004Moraes C, Fouque D, Amaral AC et al. Trimethylamine N-Oxide From Gut Microbiota in Chronic Kidney Disease Patients: Focus on Diet. J Ren Nutr 2015; 25(6):459-465. doi: 10.1053/j.jrn.2015.06.004Machowska A, Carrero JJ, Lindholm B et al. Therapeutics targeting persistent inflammation in chronic kidney disease. Transl Res 2016; 167(1):204-213. doi: 10.1016/j.trsl.2015.06.012Machowska A, Carrero JJ, Lindholm B et al. Therapeutics targeting persistent inflammation in chronic kidney disease. Transl Res 2016; 167(1):204-213. doi: 10.1016/j.trsl.2015.06.012Tzanno-Martins C, Biavo BM, Ferreira-Filho O et al. Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis. Int J Immunopathol Pharmacol 2014; 27(1):25-35Tzanno-Martins C, Biavo BM, Ferreira-Filho O et al. Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis. Int J Immunopathol Pharmacol 2014; 27(1):25-35Rossi M, Johnson DW, Campbell KL. The Kidney-Gut Axis: Implications for Nutrition Care. J Ren Nutr 2015; 25(5):399-403. doi: 10.1053/j.jrn.2015.01.017Rossi M, Johnson DW, Campbell KL. The Kidney-Gut Axis: Implications for Nutrition Care. J Ren Nutr 2015; 25(5):399-403. doi: 10.1053/j.jrn.2015.01.017Sun PP, Perianayagam MC, Jaber BL. Endotoxinbinding affinity of sevelamer: a potential novel anti-inflammatory mechanism. Kidney Int Suppl 2009; (114):S20-5. doi: 10.1038/ki.2009.403Sun PP, Perianayagam MC, Jaber BL. Endotoxinbinding affinity of sevelamer: a potential novel anti-inflammatory mechanism. Kidney Int Suppl 2009; (114):S20-5. doi: 10.1038/ki.2009.403Rodriguez-Osorio L, Zambrano DP, Gracia-Iguacel C et al. Use of sevelamer in chronic kidney disease: beyond phosphorus control. Nefrologia 2015; 35(2):207-217. doi: 10.1016/j.nefro.2015.05.022Rodriguez-Osorio L, Zambrano DP, Gracia-Iguacel C et al. Use of sevelamer in chronic kidney disease: beyond phosphorus control. Nefrologia 2015; 35(2):207-217. doi: 10.1016/j.nefro.2015.05.022Mafra D, Fouque D. Gut microbiota and inflammation in chronic kidney disease patients. Clin Kidney J 2015; 8(3):332-334. doi: 10.1093/ckj/sfv026Mafra D, Fouque D. Gut microbiota and inflammation in chronic kidney disease patients. Clin Kidney J 2015; 8(3):332-334. doi: 10.1093/ckj/sfv026Wing MR, Patel SS, Ramezani A et al. Gut microbiome in chronic kidney disease. Exp Physiol 2016; 101(4):471-477. doi: 10.1113/EP085283Wing MR, Patel SS, Ramezani A et al. Gut microbiome in chronic kidney disease. Exp Physiol 2016; 101(4):471-477. doi: 10.1113/EP085283Coulliette AD, Arduino MJ. Hemodialysis and water quality. Semin Dial 2013; 26(4):427-438. doi: 10.1111/sdi.12113Coulliette AD, Arduino MJ. Hemodialysis and water quality. Semin Dial 2013; 26(4):427-438. doi: 10.1111/sdi.12113Schiffl H. High-flux dialyzers, backfiltration, and dialysis fluid quality. Semin Dial 2011; 24(1):1-4. doi: 10.1111/j.1525139X.2010.00786.xSchiffl H. High-flux dialyzers, backfiltration, and dialysis fluid quality. Semin Dial 2011; 24(1):1-4. doi: 10.1111/j.1525139X.2010.00786.xGlorieux G, Hulko M, Speidel R et al. Looking beyond endotoxin: a comparative study of pyrogen retention by ultrafilters used for the preparation of sterile dialyis fluid. Sci Rep 2014; 4:6390. doi: 10.1038/srep06390Glorieux G, Hulko M, Speidel R et al. Looking beyond endotoxin: a comparative study of pyrogen retention by ultrafilters used for the preparation of sterile dialyis fluid. Sci Rep 2014; 4:6390. doi: 10.1038/srep06390Kashiwagi T, Sato K, Kawakami S et al. The performance evaluation of endotoxin retentive filters in haemodialysis. J Nippon Med Sch 2011; 78(4):214-223Kashiwagi T, Sato K, Kawakami S et al. The performance evaluation of endotoxin retentive filters in haemodialysis. J Nippon Med Sch 2011; 78(4):214-223Glorieux G, Neirynck N, Veys N, Vanholder R. Dialysis water and fluid purity: more than endotoxin. Nephrol Dial Transplant 2012; 27(11):4010-4021. doi: 10.1093/ndt/gfs306Glorieux G, Neirynck N, Veys N, Vanholder R. Dialysis water and fluid purity: more than endotoxin. Nephrol Dial Transplant 2012; 27(11):4010-4021. doi: 10.1093/ndt/gfs306Bowry SK, Gatti E, Vienken J. Contribution of polysulfone membranes to the success of convective dialysis therapies. Contrib Nephrol 2011; 173:110-118. doi: 10.1159/000328960Bowry SK, Gatti E, Vienken J. Contribution of polysulfone membranes to the success of convective dialysis therapies. Contrib Nephrol 2011; 173:110-118. doi: 10.1159/000328960Thomas M, Moriyama K, Ledebo I. AN69: Evolution of the world’s first high permeability membrane. Contrib Nephrol 2011; 173:119-129. doi: 10.1159/000328961Thomas M, Moriyama K, Ledebo I. AN69: Evolution of the world’s first high permeability membrane. Contrib Nephrol 2011; 173:119-129. doi: 10.1159/000328961Perego AF. Adsorption techniques: dialysis sorbents and membranes. Blood Purif 2013; 35 Suppl 2:48-51. doi: 10.1159/000350848Perego AF. Adsorption techniques: dialysis sorbents and membranes. Blood Purif 2013; 35 Suppl 2:48-51. doi: 10.1159/000350848Aucella F, Gesuete A, Vigilante M et al. Adsorption dialysis: from physical principles to clinical applications. Blood Purif 2013; 35 Suppl 2:42-47. doi: 10.1159/000350847Aucella F, Gesuete A, Vigilante M et al. Adsorption dialysis: from physical principles to clinical applications. Blood Purif 2013; 35 Suppl 2:42-47. doi: 10.1159/000350847Tijink MS, Wester M, Sun J et al. A novel approach for blood purification: mixed-matrix membranes combining diffusion and adsorption in one step. Acta Biomater 2012; 8(6):2279-2287. doi: 10.1016/j.actbio.2012.03.008Tijink MS, Wester M, Sun J et al. A novel approach for blood purification: mixed-matrix membranes combining diffusion and adsorption in one step. Acta Biomater 2012; 8(6):2279-2287. doi: 10.1016/j.actbio.2012.03.008Tijink MS, Kooman J, Wester M et al. Mixed matrix membranes: a new asset for blood purification therapies. Blood Purif 2014; 37(1):1-3. doi: 10.1159/000356226Tijink MS, Kooman J, Wester M et al. Mixed matrix membranes: a new asset for blood purification therapies. Blood Purif 2014; 37(1):1-3. doi: 10.1159/000356226Li L, Ling Y, Huang M et al. Heparin inhibits the inflammatory response induced by LPS and HMGB1 by blocking the binding of HMGB1 to the surface of macrophages. Cytokine 2015; 72(1):3642. doi: 10.1016/j.cyto.2014.12.010Li L, Ling Y, Huang M et al. Heparin inhibits the inflammatory response induced by LPS and HMGB1 by blocking the binding of HMGB1 to the surface of macrophages. Cytokine 2015; 72(1):3642. doi: 10.1016/j.cyto.2014.12.010Li X, Liu Y, Wang L et al. Unfractionated heparin attenuates LPS-induced IL-8 secretion via PI3K/Akt/NF-κB signaling pathway in human endothelial cells. Immunobiology 2015; 220(3):399-405. doi: 10.1016/j.imbio.2014.10.008Li X, Liu Y, Wang L et al. Unfractionated heparin attenuates LPS-induced IL-8 secretion via PI3K/Akt/NF-κB signaling pathway in human endothelial cells. Immunobiology 2015; 220(3):399-405. doi: 10.1016/j.imbio.2014.10.008Li X, Li X, Zheng Z et al. Unfractionated heparin suppresses lipopolysaccharide-induced monocyte chemoattractant protein-1 expression in human microvascular endothelial cells by blocking Kruppel-like factor 5 and nuclear factor-κB pathway. Immunobiology 2014; 219(10):778-785. doi: 10.1016/j.imbio.2014.06.005Li X, Li X, Zheng Z et al. Unfractionated heparin suppresses lipopolysaccharide-induced monocyte chemoattractant protein-1 expression in human microvascular endothelial cells by blocking Kruppel-like factor 5 and nuclear factor-κB pathway. Immunobiology 2014; 219(10):778-785. doi: 10.1016/j.imbio.2014.06.005Li X, Zheng Z, Li X, Ma X. Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-κB activation on endothelial cell. Cytokine 2012; 60(1):114-121. doi: 10.1016/j.cyto.2012.06.008Li X, Zheng Z, Li X, Ma X. Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-κB activation on endothelial cell. Cytokine 2012; 60(1):114-121. doi: 10.1016/j.cyto.2012.06.008Li X, Zheng Z, Mao Y, Ma X. Unfractionated heparin promotes LPS-induced endothelial barrier dysfunction: a preliminary study on the roles of angiopoietin/Tie2 axis. Thromb Res 2012; 129(5):e223-228. doi: 10.1016/j.thromres.2012.03.003Li X, Zheng Z, Mao Y, Ma X. Unfractionated heparin promotes LPS-induced endothelial barrier dysfunction: a preliminary study on the roles of angiopoietin/Tie2 axis. Thromb Res 2012; 129(5):e223-228. doi: 10.1016/j.thromres.2012.03.003Luan ZG, Naranpurev M, Ma XC. Treatment of low molecular weight heparin inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats. Inflammation 2014; 37(3):924-932. doi: 10.1007/s10753-014-9812-6Luan ZG, Naranpurev M, Ma XC. Treatment of low molecular weight heparin inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats. Inflammation 2014; 37(3):924-932. doi: 10.1007/s10753-014-9812-6

The authors declare that there are no conflicts of interest present.